ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
introductionWhether Alzheimer's disease (AD) blood biomarker-cognition associations differ across cognitive domains, analytic context, and biomarker modeling strategy in population-based cohorts is unclear.
methodsIn 1170 older adults from the Health and Retirement Study Harmonized Cognitive Assessment Protocol (HRS-HCAP), we examined cross-sectional (2016) and prospective (2016 to 2022) associations of blood phosphorylated tau at threonine 181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and amyloid beta 42/40 ratio (Aβ42/40) with memory, executive function, language, visuospatial ability, and global cognition using individual-biomarker, principal component analysis-derived composite, and multi-biomarker panel models.
resultsCross-sectionally, NfL and GFAP showed the broadest associations with cognitive performance. In simultaneous models of baseline-adjusted follow-up cognition, p-tau181 was associated with lower memory ( DISCUSSION: AD blood-based biomarker-cognition associations were domain-differentiated and context-dependent: Concurrent associations did not reliably indicate associations with cognition 6 years later, and only p-tau181 showed formal evidence of relative memory-versus-executive selectivity. Exploratory pairwise comparisons highlighted p-tau181 + GFAP for follow-up memory and global cognition, warranting independent evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.